Sys Rev Pharm 2024; 15(8): 271-272
A multifaceted review journal in the field of pharmacy
E-ISSN 0976-2779 P-ISSN 0975-8453/DOI: 10.31858/0975-8453.15.8.271-272

Short Communication

# Adverse Drug Reaction Monitoring: Prospects and Impending Challenges in Pharmacovigilance for Chemotherapeutic Agents

**Gaurav Kant Saraogi, Seemu Singh, Arshita Kumari*, Rajeshwar Prajapati**
Department of Pharmacy, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India

*Article History:* *Submitted: 06.08.2024* *Accepted: 22.08.2024* *Published: 29.08.2024*

ABSTRACT

Chemotherapy is one of the important components of treatment for many cancers. Anti-neoplastic agents are used with caution due to their high toxicity and narrow therapeutic window. Studies describing pattern of adverse drug reactions in cancer chemotherapy patients are less in India. This study aims to evaluate the pattern of Adverse Drug Reactions (ADRs) due to cancer chemotherapy in hospitalized patients and to assess the causality and severity of these reactions. This hospital-based prospective observational study was conducted at Sri Aurobindo Hospital, Indore, Madhya Pradesh among the newly diagnosed cases of different type of cancers of both genders between the ages of (25-70) years who required chemotherapy treatment. The prescribing pattern of chemotherapy drugs associated adverse effects and potential risk factors for the development of adverse effects was studied. An ADR causality was assessed by the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) Naranjo algorithm was used to identify the predictors related to chemotherapy-induced adverse effects. Most common ADR observed were peripheral neuropathy, shivering, anemia, neutropenia, thrombocytopenia and needle phobia. In this study, gastric cancer was most commonly seen followed by esophageal cancer.

**Keywords:** Chemotherapy, Adverse drug reactions, Causality assessment, Cancer

***Correspondence:** Arshita Kumari, Department of Pharmacy, Sri Aurobindo Institute of Pharmacy, Indore, Madhya Pradesh, India, E-mail: arshita.kumar-iphdpb2022@saip.ac.in

## INTRODUCTION

Chemotherapeutic agents, while essential for cancer treatment, are notorious for their ADRs. These reactions can range from mild to life-threatening conditions, impacting patient's compliance and treatment efficacy. The field of pharmacovigilance aims to systematically detect, assess, understand and prevent ADRs associated with these potent drugs. As the perspective of cancer treatment evolves with new drugs and combinations, the role of pharmacovigilance becomes increasingly critical. Chemotherapy has revolutionized cancer treatment, significantly improving patient outcomes. However, its use is often accompanied by innumerable ADRs, ranging from mild to life-threatening reactions. Pharmacovigilance plays a pivotal role in monitoring and mitigating these ADRs, ensuring patient safety and optimizing treatment efficacy. This article explores the current view of ADR monitoring in chemotherapeutic agents, outlining both the progress made and the challenges ahead in the future.

## DESCRIPTION

### *Current state of pharmacovigilance*

Pharmacovigilance encompasses various activities aiming at detecting, assessing, understanding and preventing ADRs. Traditional methods, such as spontaneous reporting systems and clinical trials, form the foundation of pharmacovigilance efforts. However, these methods have limitations, including underreporting with lack of real-time data. To address these challenges, innovative approaches, such as data mining of Electronic Health Records (EHRs) and social media monitoring, are being increasingly utilized, enabling the rapid detection of ADR signals and facilitating proactive risk management.

### *Challenges in pharmacovigilance of chemotherapeutic agents*

Chemotherapeutic agents pose unique challenges to pharmacovigilance due to their complex mechanisms of action, narrow therapeutic indices and diverse ADR profiles. Furthermore, cancer patients often receive combination therapies, increasing the complexity of ADR monitoring. Additionally, ADRs associated with chemotherapeutic agents may manifest weeks to months after initiation, necessitating long-term surveillance efforts. Moreover, the heterogeneity of cancer types and patient populations further complicates ADR detection and management.

### *Prospects in pharmacovigilance*

Despite these challenges, advancements in pharmacovigilance offer promising prospects for ADR monitoring in chemotherapeutic agents. Integrated databases, such as the FDA's Adverse Event Reporting System (FAERS) and the WHO's VigiBase, facilitate global data sharing and signal detection (WHO, 2002). Furthermore, the advent of Artificial Intelligence (AI) and machine learning algorithms enables the analysis of vast datasets, identifying previously unrecognized ADR patterns and associations.

### *Advancements in pharmacovigilance*

**Technological integration:** Big data and machine learning technologies enable the analysis of large datasets to identify potential ADRs and predict trends. Further, pharmacogenomics would be beneficial in understanding the genetic basis of drug reactions which allows for personalized medicine, reducing the incidence of ADRs by modifying the treatments to individual genetic profiles. Likewise, global collaborations can facilitate better ADR detection. Initiatives like the WHO's Programme for International Drug Monitoring (PIDM) favour the sharing of ADR data across countries, enhancing the collective ability to detect and respond to drug safety issues.

### *Methods of ADR detection*

**Spontaneous Reporting Systems (SRS):** These systems, including databases like FAERS, rely on Healthcare Professionals

(HCPs) and patients to report ADRs (FDA US, 2021). However, underreporting remains a significant limitation.

**Active surveillance:** More proactive than SRS, methods such as cohort event monitoring and registries provide real-time data on ADRs.

**E-health and data mining:** Advanced technologies such as EHRs, AI and data mining techniques are increasingly used to identify patterns and predict ADRs.

### *Current state of ADR monitoring*

**Regulatory frameworks and guidelines:** International guidelines by organizations such as the WHO and the International Council for Harmonisation (ICH) of technical requirements for pharmaceuticals for human use set the standards for ADR monitoring (ICH, 2016; WHO, 2001). National agencies like the Food and Drug Administration (FDA) in the United States of America (USA) and the European Medicines Agency (EMA) enforce these guidelines, ensuring that pharmaceutical companies maintain robust pharmacovigilance systems (EMA, 2018).

### *Challenges in ADR monitoring*

**Underreporting and data quality:** Addressing underreporting and improving data quality in ADR monitoring is crucial for enhancing drug safety. Strategies such as increasing awareness among HCPs, simplifying reporting processes and ensuring access to necessary tools which can help mitigate these issues. By fostering the culture of proactive reporting and ensuring high-quality data collection, healthcare systems can protect patients from potential medication-related harms in a better way, thereby reducing ADRs.

**Complexity of chemotherapeutic regimens:** The use of combination therapies complicates the attribution of specific ADRs to individual drugs. Delayed onset of some ADRs can make it challenging to establish causal relationships.

**Regulatory and ethical issues:** Variability in regulatory requirements across regions can hinder the harmonization of ADR data. Ethical concerns regarding the patient privacy and consent in the collection are significant in the use of health data for pharmacovigilance purposes.

## CONCLUSION

Pharmacovigilance for chemotherapeutic agents is a dynamic field with significant potential to improve patient safety. While advancements in technology and global cooperation offer potential prospects, challenges such as underreporting, complex treatment regimens and resource limitations must be addressed. By enhancing reporting systems, leveraging emerging technologies and fostering international collaboration, the pharmacovigilance community can better be monitored, managed and can mitigate the risks associated with chemotherapeutic agents, ultimately improving outcomes for cancer patients.

However, pharmacovigilance plays a critical role in ensuring the safe and effective use of chemotherapeutic agents. While challenges persist, on-going technological advancements and collaborative efforts hold potential for improving ADR monitoring and management. By leveraging emerging technologies, enhancing regulatory frameworks and fostering interdisciplinary collaboration, we can mitigate the risks associated with chemotherapy and optimize patient outcomes in the fight against cancer.

## FUTURE SCOPE

### *Enhancing reporting systems*

Educating healthcare providers and patients about the importance of ADR reporting can improve data collection. This can be beneficial in simplifying the reporting processes and integrating them into routine clinical workflows which can encourage more consistent reporting.

### *Leveraging technology*

Expanding the use of AI and machine learning to analyse EHRs and social media for real-time ADR detection can be advantageous. Further, investing in pharmacogenomic research to further personalize cancer treatment would help to minimize ADRs.

### *Strengthening global networks*

Promoting international collaboration and data sharing through platforms like VigiBase to build more comprehensive understanding of ADRs, which would subsequently, standardize regulatory frameworks to facilitate consistent and reliable ADR monitoring globally.

## REFERENCES

1. The importance of pharmacovigilance. World Health Organization (WHO). 2002.
2. Questions and answers on FDA's Adverse Event Reporting System (FAERS). FDA US. 2021.
3. Efficacy guidelines: International Council for Harmonisation (ICH). 2016.
4. The WHO Programme for International Drug Monitoring. World Health Organization (WHO). 2001.
5. Guidelines on Good Pharmacovigilance Practices (GVP). European Medicines Agency (EMA). 2018.